MedPath

Actinogen XanaMIA ACW0009 Phase 2b Trial for MCI and Mild Alzheimer's Disease

The Actinogen XanaMIA ACW0009 Phase 2b trial is seeking participants aged 50 or older diagnosed with MCI or mild Alzheimer's disease for a 9-month study involving daily oral tablets, with a 50% chance of receiving a placebo.

Who Can Participate

  • Age and Gender: Male or female, aged 50 years or older
  • Diagnosis: Must be diagnosed with Mild Cognitive Impairment (MCI) or mild Alzheimer’s disease
  • Study Partner: Must have an identified, reliable study partner
  • Medication: If using medications for Alzheimer’s disease symptoms, doses must be stable for at least 3 months prior to screening

Trial Details

  • Duration: 9 months
  • Visits: Week 1, 2, 4, 8, 12, 16, 20, 24, 36, safety follow-up (10 site visits) + 2 telephone call visits
  • Medication: Oral tablet once a day
  • Placebo: 50% chance of receiving a placebo
For further information, interested individuals can contact Paula Mather, Clinical Trial Coordinator, at Ph: 08 9389 6433 or Email: aarfctd@alzheimersresearch.org.au.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Blarcamesine Shows Sustained Cognitive Benefits in Early Alzheimer's Patients

Anavex Life Sciences' blarcamesine demonstrates significant reduction in clinical decline over three years for early Alzheimer's patients.
Delayed-start analysis reveals early treatment with blarcamesine leads to greater cognitive stability, highlighting the importance of early intervention.

Actinogen Medical Expands Alzheimer's Drug Trial to US

Actinogen Medical Limited has initiated a significant phase 2b/3 trial for its Alzheimer's treatment, Xanamem, with the first US participant enrolled. The trial, spanning 25 sites in the US and Australia, aims to assess the drug's effects on cognitive and functional measures in patients, with interim results anticipated in 2025 and final results in 2026.

INmune Bio Completes Enrollment in Phase 2 Alzheimer's Trial Targeting Neuroinflammation

INmune Bio has finalized patient randomization for its Phase 2 trial (AD02) in early Alzheimer's disease, enrolling a total of 208 patients.
The trial focuses on individuals with elevated neuroinflammation biomarkers, with 56% having mild Alzheimer's and 44% with mild cognitive impairment.

Sinaptica's Neuromodulation Device Shows Promise in Phase II Alzheimer's Trial

Sinaptica Therapeutics' SinaptiStim system significantly slowed Alzheimer's progression in a Phase II trial, meeting primary and key secondary endpoints.
The neuromodulation device targets the brain's default mode network (DMN) to boost adaptability and reinforce memory pathways in weekly 20-minute sessions.

Sinaptica's Neuromodulation Device Shows Promise in Phase II Alzheimer's Trial

Sinaptica Therapeutics' SinaptiStim system significantly slowed Alzheimer's progression over 12 months in a Phase II trial.
Patients receiving neuromodulation experienced a 44% reduction in disease progression compared to the placebo group.

Anavex's Blarcamesine MAA Accepted by EMA for Alzheimer's Treatment

Anavex Life Sciences' blarcamesine MAA has been accepted by the EMA for review as a potential Alzheimer's treatment, marking a regulatory milestone.
Clinical data from Phase IIb/III trials showed blarcamesine significantly improved cognition and slowed neurodegeneration in early Alzheimer's patients.

Cognition Therapeutics' CT1812 Shows Promise in Phase 2 Trials for Alzheimer's and Lewy Body Dementia

Cognition Therapeutics' CT1812 demonstrated a 95% slowing of cognitive decline in Alzheimer's patients with lower plasma p-tau217 levels in Phase 2 SHINE study.
The Phase 2 SHIMMER study of CT1812 in dementia with Lewy bodies (DLB) met its primary endpoint of safety and tolerability.

Axsome Therapeutics Announces Successful Completion of Phase 3 Clinical Trial for Alzheimer’s Disease Agitation

Axsome Therapeutics has successfully completed its Phase 3 clinical trial, ACCORD-2, for Alzheimer’s disease agitation, achieving both primary and key secondary endpoints with significant results compared to placebo.

Actinogen Optimizes XanaMIA Phase 2b Alzheimer's Disease Trial Design

Actinogen Medical Limited has announced optimizations to its XanaMIA Phase 2b trial for mild-to-moderate Alzheimer's disease, reducing costs by AUD 30 million and speeding up initial results. The trial now focuses on a 10 mg dose group, enrolling 220 patients, and includes Australian sites for the first 100 patients. Additionally, the XanaCIDD trial for cognitive impairment associated with depression has expanded to include UK sites, with results expected by mid-2024.

Anavex's Phase 2b/3 Trial of Blarcamesine Shows Promising Results in Alzheimer's Disease Treatment

Anavex Life Sciences Corp. announced significant findings from its Phase 2b/3 trial of blarcamesine (ANAVEX®2-73) for early Alzheimer's disease, showing a notable slowing in cognitive decline and reduction in amyloid beta biomarkers, alongside a decrease in brain atrophy rate.

Reference News

[1]
Actinogen XanaMIA ACW0009 (Phase 2b)
alzheimersresearch.org.au · Apr 23, 2024

Eligible participants: aged 50+ with MCI or mild Alzheimer’s, stable medication for 3 months, and a study partner. Invol...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy